{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-008352","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2024-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.610363+00:00","generated_at":"2026-06-06T00:04:32.608539+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ocuphire Pharma appoints Nirav Jhaveri as CFO and Ash Jayagopal as Chief Scientific Officer","bullets":["Nirav Jhaveri appointed CFO effective Feb 12, 2024; base salary $410k, equity awards: 210k options + 140k RSUs.","Ash Jayagopal appointed Chief Scientific and Development Officer; 15+ years retinal disease experience, previously at Opus Genetics and Roche.","Jhaveri previously CFO at Insilico Medicine and Journey Medical; over 20 years biopharma finance experience.","Both appointments effective Feb 12, 2024, as company advances APX3330 phase 3 in diabetic retinopathy.","Jhaveri eligible for discretionary annual cash bonus up to 45% of base salary; severance includes 0.75x salary plus prorated bonus."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-008352","json":"https://secwatch.observer/filing/0001140361-24-008352.json","markdown":"https://secwatch.observer/filing/0001140361-24-008352.md","text":"https://secwatch.observer/filing/0001140361-24-008352.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000114036124008352/0001140361-24-008352-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000114036124008352/ef20021883_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T00:04:32.608539+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e306896fd6","claim":"Nirav Jhaveri was appointed as Chief Financial Officer at Opus Genetics, Inc..","evidence_excerpt":"On February 14, 2024, Ocuphire Pharma, Inc., (the “Company”) announced the appointment of Nirav Jhaveri as the Company’s Chief Financial Officer (“CFO”), effective February 12, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036124008352/0001140361-24-008352-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}